| 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| CDMO原料药及中间体(元) | 251,162,781.51 | 365,801,400.02 | 174,015,984.58 |
| 仿制药原料药及中间体(元) | 1,131,315,045.91 | 1,994,110,930.35 | 992,215,272.43 |
| 制剂(元) | 179,233,347.65 | 254,761,203.94 | 97,029,467.17 |
| 其他(元) | - | 16,134,709.09 | 2,143,093.02 |
| 营业成本(元) | |||
| CDMO原料药及中间体(元) | 114,679,924.81 | 184,777,218.39 | 83,665,196.30 |
| 仿制药原料药及中间体(元) | 768,657,424.96 | 1,409,954,712.61 | 689,545,055.10 |
| 制剂(元) | 74,934,513.83 | 113,362,305.29 | 42,348,144.29 |
| 其他(元) | - | 10,986,488.43 | 1,481,229.58 |
| 毛利(元) | |||
| CDMO原料药及中间体(元) | 136,482,856.70 | 181,024,181.63 | 90,350,788.28 |
| 仿制药原料药及中间体(元) | 362,657,620.95 | 584,156,217.74 | 302,670,217.33 |
| 制剂(元) | 104,298,833.82 | 141,398,898.65 | 54,681,322.88 |
| 其他(元) | - | 5,148,220.66 | 661,863.44 |
| 毛利率(%) | |||
| CDMO原料药及中间体(%) | 54.34 | 49.49 | 51.92 |
| 仿制药原料药及中间体(%) | 32.06 | 29.29 | 30.50 |
| 制剂(%) | 58.19 | 55.50 | 56.36 |
| 其他(%) | - | 31.91 | 30.88 |
| 收入构成(%) | |||
| CDMO原料药及中间体(%) | 16.08 | 13.90 | 13.75 |
| 仿制药原料药及中间体(%) | 72.44 | 75.80 | 78.41 |
| 制剂(%) | 11.48 | 9.68 | 7.67 |
| 其他(%) | - | 0.61 | 0.17 |
| 毛利构成(%) | |||
| CDMO原料药及中间体(%) | 22.62 | 19.86 | 20.15 |
| 仿制药原料药及中间体(%) | 60.10 | 64.07 | 67.51 |
| 制剂(%) | 17.28 | 15.51 | 12.20 |
| 其他(%) | - | 0.56 | 0.15 |